Proventil HFA Inhalation Aerosol

3M Pharmaceuticals

Approval Status
Approved June 1999

Treatment for
Pulmonary/Respiratory Diseases


The approval of Proventil HFA (albuterol sulfate) Inhalation Aerosol covers a supplemental new drug application that provides for the following: lowering the age from 12 years to 4 years and older for the treatment or prevention of

  • bronchospasm with reversible obstructive airway disease
  • exercise-induced bronchospasm
Proventil HFA Inhalation Aerosol Drug Information

The Proventil HFA Inhalation Aerosol drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top